Multidrug-Resistant Tuberculosis In A Referral Center In Rome: 2011- 2016.
MDR-TB
XDR-TB
drug-susceptibility testing
tuberculosis
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
06
2019
accepted:
12
08
2019
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in low incidence countries in Europe. The aim of this study was to attempt to have a better insight into the trends of MDR-TB in the metropolitan area of Rome, within the Italian and the foreign-born population, based on microbiological and demographic data. We performed a prospective study, collecting microbiological data based on phenotypic drug-resistant testing (DST) of TB strains consecutively isolated in a referral hospital in Rome, the capital city of a low TB incidence country, over a 6-year period, and correlated them to the geographical origin of patients. This study was carried out in a referral hospital for patients with drug-resistant TB from the whole region. Drug-resistance data from 926 patients with a microbiological diagnosis of TB from 2011 to 2016 show a 5.5% rate of MDR-TB, mostly occurring in patients born in a single East European country, that has a high incidence of MDR-TB. The strains isolated from these patients frequently carry additional resistances, leading to an increased risk of developing extensively drug-resistant (XDR) TB. In the great metropolitan area of Rome, MDR-TB more frequently occurs in patients who were born in a single country from Eastern Europe known to have high rates of MDR-TB and long-time residents in Italy. Recent immigrants from non-European countries do not appear to contribute to the rates of MDR-TB reported in this article. This knowledge of local TB trends could help improve the measures of surveillance and prevention of disease.
Identifiants
pubmed: 31695446
doi: 10.2147/IDR.S218744
pii: 218744
pmc: PMC6805241
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3275-3281Informations de copyright
© 2019 Cannas et al.
Déclaration de conflit d'intérêts
Dr E Girardi reports grants from Mylan, grants from Gilead, personal fees from ViiV, personal fees from Gilead, personal fees from Angelini, personal fees from Mylan, personal fees from Otsuka, and non-financial support from Gilead, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
Eur Respir J. 2018 Jul 19;52(1):
pubmed: 29724919
Thorax. 2006 Feb;61(2):158-63
pubmed: 16254056
Int J Infect Dis. 2017 Mar;56:85-89
pubmed: 27836793
Euro Surveill. 2017 Mar 23;22(12):
pubmed: 28367798
Euro Surveill. 2017 Jul 6;22(27):
pubmed: 28703099
Ann Ist Super Sanita. 2016 Oct-Dec;52(4):603-607
pubmed: 27999235
Clin Microbiol Infect. 2017 Mar;23(3):141-146
pubmed: 27665703
Eur Respir J. 2014 Apr;43(4):1132-41
pubmed: 24558181
Int J Tuberc Lung Dis. 2017 Jul 1;21(7):727-736
pubmed: 28633696
Eur Respir J. 2015 Jan;45(1):150-60
pubmed: 25261327
Lancet. 2015 Dec 5;386(10010):2324-33
pubmed: 26515676
Lancet Respir Med. 2017 Mar 15;:
pubmed: 28344011
Presse Med. 2017 Mar;46(2 Pt 2):e5-e11
pubmed: 28256381
Travel Med Infect Dis. 2016 Nov - Dec;14(6):588-590
pubmed: 27913312
BMC Med. 2016 Mar 23;14:48
pubmed: 27004556